An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy
Almon, Einat, Khoury, Tawfik, Drori, Ariel, Gingis-Velitski, Svetlana, Alon, Sari, Chertkoff, Raul, Mushkat, Mordechai, Shaaltiel, Yoseph, Ilan, YaronLanguage:
english
Journal:
Journal of Immunological Methods
DOI:
10.1016/j.jim.2017.03.023
Date:
April, 2017
File:
PDF, 2.11 MB
english, 2017